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Fibroblast extracellular matrix (ECM) contains two
forms of insulin-like growth factor-binding proteins
(IGFBPs), IGFBP-3 and IGFBP-5. These studies were
undertaken to identify the regions within IGFBP-5 that
mediate its binding to fibroblast ECM. Synthetic pep-
tides were prepared that were homologous with two
regions of basic amino acids within IGFBP-5 (Arg201-
Arg218 and Ala131-Thr141). Increasing concentrations of
both peptides competed with IGFBP-5 for binding to
ECM but the Arg201-Arg218 peptide was more potent. Mu-
tagenesis was used to define the effect of substituting
for these basic residues on ECM binding. Substitution
for two peptide B residues K134A and R136A reduced
binding by 40%. Substitution of a single basic residue
within the peptide A region (K211N) reduced binding to
ECM by 49%. Substitution for K211N, K134A, and R136A
reduced binding by 52%. More extensive substitutions in
the peptide A region, e.g. K211N,R214A,K217A,R218N,
resulted in a greater (e.g. 88%) decrease. The positional
location of basic residues appeared to be more impor-
tant than the total number of substitutions since the
mutant K202N,K206A,R207A had a 79% reduction in
ECM binding. Two basic regions of IGFBP-5 contribute
to its binding to ECM, but the region containing amino
acids 201–218 has a greater contribution. ECMbinding is
mediated by charged residues and acts to stabilize
IGFBP-5 by protecting it from proteolysis.
Connective tissue cells are embedded in a three-dimensional
extracellular matrix (ECM).1 Cellular attachment to the ECM
results not only in anchorage dependence but also contributes
to changes in cell shape, migration, and division (1, 2). Insulin-
like growth factor binding proteins (IGFBPs) are soluble pro-
teins that are present in extracellular fluids (3, 4). In recent
studies, we have determined that two forms of IGFBPs,
IGFBP-3 and IGFBP-5, are localized in fibroblast ECM and
that IGFBP-1, -2, and -4 do not bind to fibroblast ECM (5). The
association of IGFBP-5 with ECM results in a functional dif-
ference in fibroblast responsiveness to IGF-I. Specifically,
when IGFBP-5 is ECM-associated, its affinity for IGF-I is low-
ered by approximately 8-fold (5). This lowering of its affinity
may allow IGF-I to be more readily accessible to cell surface
receptors since the addition of IGFBP-5 plus IGF-I results in a
60% increase in fibroblast growth in 48 h, whereas IGF-I alone
results in a 31% increase. If type IV collagen is used in place of
ECM, the fibroblast growth response to IGFBP-5 plus IGF-I is
enhanced by 52%. Since binding of IGFBP-5 to ECM also pro-
tects it from degradation (5, 6), IGFBP-5 localization in ECM
may provide a mechanism for concentrating IGF-I in discrete
areas making it available to stimulate a proliferative response.
Increasing the salt concentration in the incubation buffer
results in decreased binding of IGFBP-5 to fibroblast ECM (5).
This suggests that the binding is ionic and not hydrophobic.
Furthermore, IGFBP-5 binds to glycosaminoglycans, and gly-
cosaminoglycan binding reduces the affinity of IGFBP-5 for
IGF-I (7). Since glycosaminoglycans are present in ECM and
protein binding to glycosaminoglycans is often ionic, this sug-
gests that charged amino acids in IGFBP-5 are important for
ECM binding. Unlike IGFBP-1, -2, -4, and -6, IGFBP-3 and -5
contain a region near the carboxyl terminus of the molecule in
which 10 of 18 amino acids are basic (8). IGFBP-5 also contains
another highly basic region in its central core region in which
six of seven consecutive amino acids are basic (9). In order to
determine if the NaCl-inhibitable binding of IGFBP-5 to ECM
is mediated through these basic regions, we synthesized two
peptides corresponding to these regions and used them to study
the IGFBP-5 interaction with ECM. In addition, we used in
vitro mutagenesis to convert several charged residues within
these two regions of native IGFBP-5 to neutral ones in order to
determine the effect of these substitutions on ECM binding.
EXPERIMENTAL PROCEDURES
Preparation of Extracellular Matrix—Human fetal dermal fibro-
blasts (GM-00010) were purchased from Coriell Institute, Camden, NJ
and were maintained in Eagle’s minimum essential media (Hazelton
Systems, Denver, PA) supplemented with 10% calf serum (Colorado
Serum Co., Denver), 100 mg/ml pyruvate, 30 mg/ml asparagine, 21 mg/ml
serine, 100 units/ml penicillin, and 100 mg/ml streptomycin (Life Tech-
nologies, Inc.). Cells were grown on two types of culture dishes depend-
ing upon the purpose of the experiment. If the purpose was to compete
with endogenously synthesized IGFBP-5, the cells were plated on 24-
well plates, (Falcon No. 3047, Falcon Division, Becton Dickinson Lab-
oratories, Rutherford, NJ). If the binding of exogenously added
IGFBP-5 was to be tested, the cells were plated on positively charged
24-well plates (Primaria, Falcon) and grown for 7–10 days to conflu-
ence. Primaria plates were used in order to minimize nonspecific bind-
ing of IGFBP-5 to the dishes. The cells that were plated on Primaria
plates were maintained in 10% fetal bovine serum (Hyclone Laborato-
ries, Logan, UT) rather than calf serum because this was shown to limit
the amount of endogenously synthesized IGFBP-5 that was associated
with ECM (5). The ECM was prepared as described previously (5). The
plates were kept at 4 °C during the preparation of ECM and binding
assays. When the cultures reached confluency, the medium was aspi-
rated and each well was rinsed twice with PBS. The cellular mem-
branes were removed by incubation for 5 min in 0.5% Triton X-100
(Sigma) in PBS, pH 7.4. The adherent nuclei and cytoskeletal proteins
were removed by incubation for 5 min in 25 mM ammonium acetate, pH
9.0 (10). The ECM which remained on the plates was rinsed twice in
PBS and used as a substratum for binding experiments.
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Western Ligand Blots and Immunoblots—Fibroblast ECM was pre-
pared as above and scraped from the plates into Laemmli sample buffer
(containing 3% SDS). Samples of the ECM preparations were heated to
60 °C for 10 min, and the ECM proteins were resolved by SDS-PAGE
(using 12.5% gels) and transferred to polyvinylidene difluoride mem-
branes (Immobilon, Millipore Corp.). For experiments done under re-
ducing conditions, 0.1 M dithiothreitol (Sigma) was added and the
solution was heated to 100 °C for 10 min. Following electrophoresis and
Western blotting, the membranes were probed with 125I-IGF-I (650,000
cpm in 5 ml). The probing and transfer buffers were as described
previously (11). Autoradiographs were prepared by exposing the filters
to hyperfilm MP, (Amersham Corp.). The autoradiographic signal in-
tensities were determined by scanning densitometry using a Hoefer
GS-300 scanner (Hoefer Scientific Instruments, San Francisco, CA). In
some experiments, image intensity was also quantified using a Phos-
phorImager, model 455, Molecular Dynamics, Sunnyvale, CA. 125I-IGF-
I was iodinated to a specific activity of 125 mCi/mg and was a gift of
Louis E. Underwood, University of North Carolina. For immunoblot-
ting, a 1 to 500 dilution of polyclonal antiserum to human IGFBP-5 was
incubated overnight at room temperature as described previously (5),
and the immunoblots were developed for 3 h using a sheep anti-guinea
pig IgG-AP conjugate (Boehringer Mannheim) using the manufactur-
er’s recommended procedure. This antiserum is specific for IGFBP-5
and has ,0.5% cross-reactivity with other forms of IGFBPs.
Preparation of Human IGFBP-5 and IGFBP-3—Human IGFBP-5
was purified to homogeneity from conditioned media from Chinese
hamster ovary (CHO) cells (ATCC, Rockville, MD) that had been stably
transfected (5). The IGFBP-5 cDNA was inserted into an expression
plasmid (pNUT) obtained from Richard Palmiter, University of Wash-
ington, Seattle, as described previously (6). The human IGFBP-5 se-
creted by the transfected CHO cells was purified using a previously
described method and was indistinguishable from IGFBP-5 that had
been purified from conditioned medium obtained from a human glio-
blastoma cell line (ATCC, 1690) as determined by SDS-PAGE with
silver staining, ligand blot, immunoblot, and the determination IGF
binding affinity (6). Recombinant human IGFBP-3 that had been puri-
fied to homogeneity from conditioned medium obtained from trans-
fected CHO cells was a gift from Genentech, Inc., South San Francisco,
CA.
Binding of Purified IGFBP-5 or IGFBP-3 to ECM—The ECM was
prepared from GM000-10 fibroblasts that had been grown to confluence
on Primaria (positively charged) 24-well plates. The ECM was rinsed
with PBS, then 0.5 ml of 0.03 M sodium phosphate, 0.1% bovine serum
albumin, pH 7.4, was added. IGFBP-5 (40 ng–2.0 mg/ml) or IGFBP-3 (80
ng/ml) was added directly to the incubation buffer. After an overnight
incubation at 4 °C, the wells were rinsed twice with PBS, and the ECM
proteins were extracted with Laemmli sample buffer containing 3%
SDS. The extracts were analyzed by SDS-PAGE followed by Western
ligand blotting using 125I-IGF-I (11) or immunoblotting (5). In some
experiments, increasing concentrations of synthetic peptides (0.045 to
10 mg/ml) were coincubated with unlabeled IGFBP-5 or IGFBP-3 (80
ng/ml) as described previously (5). To determine if the peptides could
compete for binding to ECM with endogenously synthesized IGFBP-5,
ECM was prepared from GM000-10 fibroblasts that had been cultured
in 10% calf serum on negatively charged 24-well plates (Falcon 3047).
The binding assay was performed as described previously except that
no IGFBP-5 was added to the incubation buffer. To determine if
IGFBP-5 fragments that were detected in the ECM in the presence of
peptide A were due to proteolysis, serine protease inhibitors were added
to the incubation buffer with IGFBP-5. The protease inhibitors included
3,4-dichloroisocoumarin (3,4-DCI) (Sigma), a peptide containing the
active site of a1-antichymotrypsin (12), and a peptide containing the
active site of antithrombin III, termed PB-145 (13). After overnight
incubation, the ECM was extracted and the molecular sizes of the
IGFBP-5 in the ECM and incubation buffer were estimated by immu-
noblotting (6).
Peptide Synthesis—Synthetic peptides were prepared by a previously
described method (14). They were purified to .99% purity by reverse-
phase HPLC. Two additional forms of one peptide containing amino
acid substitutions for charged residues at positions 207 and 211 were
also synthesized. A 14-amino acid synthetic peptide corresponding to
the active site of the serine protease inhibitor, a1-antichymotrypsin
(12), was also prepared and purified. A synthetic peptide containing the
active site of antithrombin III (13) was a gift from Charles Schastein,
Monsanto Inc., St. Louis, MO.
In Vitro Mutagenesis—The full-length human IGFBP-5 cDNA was
cloned into HindIII-NotI sites of the mammalian expression plasmid
pRcRSVhBP-5 which had been prepared from the plasmid pRcCMV
(Invitrogen). pRcCMV contains a bacteriophage origin of replication (f1)
that allows production of plasmid DNA in a single-stranded form suit-
able for site-directed mutagenesis. The 655-base pair cytomegalovirus
promoter was deleted from the pRcCMVhBP-5 plasmid by digestion
with restriction enzymes NruI and HindIII. The resulting 5-kilobase
linear DNA was gel-purified, and the 636-base pair Rous sarcoma virus
(RSV) long terminal repeat was generated from the plasmid pREP 9
(Invitrogen). After digestion with XbaI, the ends of the linear DNA were
blunted with T4 DNA polymerase. Digestion with HindIII produced a
fragment containing RSV long terminal repeat with ends compatible for
directional cloning intoNruI-HindIII-digested pRchBP-5. The resulting
fragment was gel-purified and ligated into pRchBP-5 using an insert to
vector ratio of 6:1 and T4 DNA ligase. Following transformation of
competent Escherichia coli, strain DH5a F9, DNA from the resulting
colonies was screened for the presence of an additional 167-base pair
EcoRI fragment in the RSV long terminal repeat containing clones.
Mutants of pRcRSVhBP-5 were generated by site-directed mutagen-
esis. Two nanograms of plasmid DNA was transfected into E. coli strain
CJ236. A fresh colony of CJ236 was used to inoculate a 60-ml culture
and grown to an optical density of 0.25–0.30 (600 nm) before infection
with helper phage R408 at a multiplicity of infection of 10:1. The culture
was grown for 5 h, and the bacteria were pelleted. Secreted phagemid
particles were precipitated in 16% polyethylene glycol, 2.8 M ammonium
acetate, and single-stranded phagemid DNA was isolated by adherence
to glassmilk according to a protocol provided by the manufacturer (Bio
101, La Jolla, CA). Complimentary oligonucleotides containing muta-
genic mismatches were synthesized by the Lineberger Comprehensive
Cancer Research Center Nucleic Acids Core facility. The following
sequences were used: acgggaaggttgcactgctttc, Lys211 3 Asn; cttcttt-
ctggcgtcgttcttcactgc, Lys134, Arg136 3 Ala; gcactgctttgccgcgtagaatc-
cattgcggtcac, Lys202 3 Asn, Lys206, and Arg207 3 Ala; gcagatgccagc-
cgcgcggccagcggaagggtt, Arg214 and Lys217 3 Ala, Arg218 3 Asn.
Synthetic oligonucleotides were phosphorylated with 15 units of T4
polynucleotide kinase for 1 h at 37 °C. Ten ml of the synthesis mixture
was used to transform E. coli strain DH5aF9. Ampicillin-resistant col-
onies were selected, and their DNA was amplified. Sequencing of dou-
ble-stranded DNA was performed by the Sequenase (U. S. Biochemical
Corp.) protocol, followed by 6% polyacrylamide, Tris-borate-EDTA, urea
gel electrophoresis, and autoradiography (15). The clones containing
the correct sequences were then amplified, and plasmid DNA was
prepared using silica gel anion exchange resin chromatography as
recommended by Qiagen (Chatsworth, CA).
Transfection of Mammalian Cells—CHO K-1 cells were obtained
from the Lineberger Comprehensive Cancer Center Tissue Culture
Facility. The cells were maintained in a-minimum essential medium,
10% fetal calf serum, supplemented with penicillin and streptomycin.
Twenty-four hours before transfection, the cells were plated into 6-well
tissue culture plates at 12,000 cells/cm2. DNA was introduced into the
cells by a standard calcium phosphate precipitation procedure (16).
DNA-calcium precipitate was formed by mixing 0.5 ml of 0.25 M CaCl2
with 10 mg of plasmid DNA and 2 mg of CaCl2 complexed DNA was
added to wells containing 3 ml of medium. The plates were incubated at
37 °C for 5 h. Calcium-containing medium was removed, and medium
containing 10% glycerol was applied for 3 min. The medium was re-
placed, and, after 48 h, the cells were trypsinized and plated in medium
containing 800 mg/ml neomycin analogue, G418. Fresh G418 was reap-
plied every 3–4 days for 10–12 days when colonies of stably transfected
cells began to appear. Colonies were isolated by cloning rings,
trypsinized, and transferred to individual wells of a 24-well plate.
Medium was analyzed by immunoblotting for production of IGFBP-5
after reaching confluency. Clones were maintained in 400 mg/ml G418.
Conditioned medium containing the mutants was collected and cen-
trifuged at 10,000 3 g for 20 min to remove cellular debris. The
IGFBP-5 mutants were purified to homogeneity as described previously
(6). The amount of each IGFBP-5 mutant was quantified by comparing
its HPLC peak area to the peak area of a known amount of wild type
IGFBP-5 that had been quantified by amino acid composition analysis.
To ensure that Western ligand blotting was a valid method estimating
the amount of each mutant that bound to ECM, the binding capacity
and affinity of each mutant for 125I-IGF-I was determined using Scat-
chard analysis (5). Since the affinity and binding capacity of each
mutant were similar to nonmutated IGFBP-5 (Table I), an IGF binding
capacity assay was used to obtain an independent estimate of the
amount of each mutant and to confirm that the values obtained using
the HPLC peak area method were correct. Increasing concentrations
(0.1 to 20 ng/ml) of each mutant were coincubated with 125I-IGF-I and
the amount of bound 125I-IGF-I determined as described previously
(17). The concentration of each mutant was estimated by comparing the
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amount of 125I-IGF-I that bound to each mutant to the amount that
bound to a known concentration of nonmutated IGFBP-5. For compet-
itive binding experiments, 125I-IGFBP-3 and -IGFBP-5 were prepared
and purified as described previously (17). The specific activities were 27
and 16 mCi/mg, respectively. 2.5 3 105 cpm of IGFBP-3 and 1.7 3 105
cpm of IGFBP-5 plus increasing concentrations of each unlabeled pro-
tein (1.9–236 pM) or peptide A (250–16,000 pM) were added to 24-well
plates containing fibroblast ECM in 0.5 ml of the binding buffer. After
14 h at 4 °C, the buffer was removed, the ECM was extracted with 0.3
N NaOH, and the bound 125I-IGFBP-3 or -5 was determined. Nonspecific
binding was determined by subtracting the counts/min bound in the
presence of a 300 pM concentration of each protein.
RESULTS
To determine if the negatively charged regions of IGFBP-5
were ECM attachment sites, synthetic peptides containing the
amino acid sequences shown in Fig. 1 (termed peptide A, B, C,
or D) were incubated with IGFBP-5 and fibroblast ECM. Li-
gand blotting of the ECM extracts showed a dark Mr 31,000
band (Fig. 2A, lane 2) and a faint Mr 38,000 band. Immuno-
blotting (Fig. 3) indicated that the Mr 31,000 band that was
detected was IGFBP-5 and that the Mr 38,000 band (Mr esti-
mate corresponds to IGFBP-3 (6)) did not react with IGFBP-5
antisera. Addition of increasing concentrations of peptide A
resulted in a decrease in the signal intensity of the Mr 31,000
band (Fig. 2A, lanes 3–5) and (Fig. 3, lanes 2–4). The addition
of increasing concentrations of peptide B also resulted in com-
petition (Fig. 2A, lanes 6–8, and Fig. 3, lanes 5–7). Scanning
densitometry of autoradiographs obtained in 3 experiments
showed that Peptide A (450 ng/ml) resulted in a 83 6 7%
reduction in band intensity and peptide B gave a 55 6 12%
decrease. Since the molar concentration of peptide B that was
added was 40% greater than peptide A, this indicates that it
was significantly less potent. Addition of peptide C or peptide D
(4.5 mg/ml) (Fig. 2B) or a peptide containing the sequence of the
active site of a1-antichymotrypsin (5.0 mg/ml) (data not shown)
resulted in no competition.
When increasing concentrations of either peptide A or B were
incubated with fibroblast ECM that contained endogenously
synthesized IGFBP-5, each peptide was capable of inhibiting
IGFBP-5 binding to the ECM (Fig. 4). To determine if these
peptides competed with IGFBP-3 for binding to ECM, human
IGFBP-3 (80 ng/ml) was incubated with ECM and increasing
concentrations of each peptide. As shown in Fig. 5, peptide A
was significantly more potent than peptide B in competing with
IGFBP-3 for binding to ECM. Scanning densitometry showed
that peptide A was 20-fold more potent than peptide B. To
confirm that peptide competition was specific, 125I-IGFBP-5 or
125I-IGFBP-3 was incubated with increasing concentrations of
each unlabeled protein or peptide A. As shown in Fig. 6, the
intact forms of each IGFBP were considerably more potent in
competing with the iodinated ligand for binding to ECM as
compared to peptide A. For IGFBP-5, a concentration of 7 pM
resulted in half-maximal competition, whereas 1.5 nM peptide
A was required. For IGFBP-3, half-maximal competition was
obtained using 59 pM supporting the conclusion that IGFBP-5
binds to the ECM with higher affinity.
The addition of increasing concentrations of peptide A re-
sulted in the appearance of IGFBP-5 fragments of 24 and 27
kDa in the ECM (Figs. 3 and 7B). In the absence of peptide A
FIG. 1. Amino acid sequence of IGFBP-5. The amino acid se-
quence of human IGFBP-5 is shown beginning with the translation
initiation residue and ending with the carboxyl terminus. The arrow
denotes the beginning of the sequence of the secreted protein. The
beginning of the sequences for each peptide termed A, B, C, and D are
noted by the letter in parentheses. Seven of the eleven amino acids in
peptide B are basic, and 10 of 18 are basic in peptide A whereas only 5
of 20 and 6 of 18 are basic in peptides C and D, respectively. The
numbers indicate the amino acid position within the secreted protein.
The peptide A sequence is also present in IGFBP-3.
FIG. 2. Ligand blot of IGFBP-5 in ECM in the presence of
peptides A and B. A, ECM was prepared from confluent fibroblast
cultures as described under “Experimental Procedures.” It was exposed
to IGFBP-5 (80 ng/ml) and increasing concentrations of peptide A or
peptide B. Following an overnight incubation, the ECM was extracted
and the proteins in the extracts were separated by SDS-PAGE, trans-
ferred to Immobilon filters, and blotted with 125I-IGF-I. The arrows
denote the IGFBP-3 and IGFBP-5 bands. Lane 1, ECM alone; lanes 2–8,
ECM plus IGFBP-5 (80 ng/ml); lane 3, peptide A (45 ng/ml); lane 4,
peptide A (450 ng/ml); lane 5, peptide A (4.5 mg/ml); lane 6, peptide B
(45 ng/ml); lane 7, peptide B (450 ng/ml); lane 8, peptide B (4.5 mg/ml).
B, lane 1, ECM alone; lanes 2–7, ECM plus IGFBP-5 (80 ng/ml); lane 3,
peptide C (450 ng/ml); lane 4, peptide C (4.5 mg/ml); lane 5, IGFBP-5
alone; lane 6, peptide D (450 ng/ml); lane 7, peptide D (4.5 mg/ml).
FIG. 3. Immunoblot showing competition for binding of
IGFBP-5 to ECM with peptides A and B. ECM was prepared, and
the binding assay was conducted as described in Fig. 2. Following
SDS-PAGE, the proteins were transferred to Immobilon filters and
immunoblotted as described under “Experimental Procedures” using a
specific guinea pig anti-IGFBP-5 antiserum. Lanes 1–7, IGFBP-5 (80
ng/ml); lane 2, peptide A (45 ng/ml); lane 3, peptide A (450 ng/ml); lane
4, peptide A (4.5 mg/ml); lane 5, peptide B (45 ng/ml); lane 6, peptide B
(450 ng/ml); lane 7, peptide B (4.5 mg/ml).
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(Fig. 7, A and B, lane 1), these fragments could not be detected
in the ECM, and minimal amounts were present in the assay
buffer. Therefore, if peptide A was omitted, the binding of
mutant and wild type IGFBP-5 binding to ECM did not appear
to be altered significantly by proteolysis. In contrast, if peptide
A was added, these fragments were detected (Fig. 7, A and B,
lane 2). Since fibroblast-conditioned medium has been shown to
contain a serine protease that cleaves IGFBP-5, we repeated
the experiment with the serine protease inhibitor 3,4-DCI in
the incubation buffer. 3,4-DCI inhibited the appearance of the
24- and 27-kDa fragments in ECM and in the assay buffer (Fig.
7, A and B, lane 4). Since the degree of reduction of intact
IGFBP-5 band intensity was similar whether or not 3,4-DCI is
added (Fig. 7B, compare lane 2 with lane 3), the conclusion that
peptide A competes with intact IGFBP-5 for binding and does
not simply reduce the signal intensity by enhancing proteolysis
appears to be valid. An antithrombin III analogue termed PB-
145, partially inhibited the appearance of proteolytic fragments
in the ECM and the assay buffer. A peptide containing the
cleavage site of a1-antichymotrypsin (Fig. 7, A and B) and
EDTA, 5 mM (data not shown), had no effect on proteolysis.
Since heparin totally inhibited IGFBP-5 binding to the ECM,
its effect on proteolysis could not be determined. The findings
suggest that in the presence of peptide A, a serine protease is
released from the ECM into the assay buffer. IGFBP-5 is then
cleaved into 24- and 27-kDa fragments which can rebind to
ECM.
Mutagenesis was used to further analyze the importance of
these basic residues in mediating ECM binding. Several mu-
tants were constructed to alter charged residues within the
peptide A and B regions (Table I). All of the mutants tested
retained high affinity for IGF-I that was similar to wild type
IGFBP-5. The effect of these mutations on ECM binding was
analyzed by Western ligand blotting (Fig. 8). Immunoblotting
was also used to confirm the Western ligand blotting results
(Fig. 9). Substitution for two basic residues within the peptide
B region K134A and R136A resulted in a 40 6 11% decrease in
ECM binding as determined by ligand blotting and scanning
densitometry (Fig. 8). The coincubation of peptide B with the
K134A,R136A mutant resulted in no further reduction in ECM
binding (data not shown) indicating that further substitutions
for basic residues within the peptide B region probably would
have had little additional effect. A single substitution in the
peptide A region, K211N, resulted in a 49 6 13% decrease in
FIG. 4. Inhibition of endogenously synthesized IGFBP-5 bind-
ing to ECM.We have previously shown that endogenously synthesized
IGFBP-5 can be detected in fibroblast ECM (5). ECM was prepared
from fibroblasts that had been cultured on negatively charged plates in
calf serum. The ECM was incubated with increasing concentrations of
peptide A and B and the IGFBP-5 remaining in the ECM after an
overnight incubation determined by immunoblotting. Lane 1, ECM
alone; lane 2, peptide A (0.5 mg/ml); lane 3, peptide A (2.0 mg/ml); lane
4, peptide A (10 mg/ml); lane 5, peptide B (0.5 mg/ml); lane 6, peptide B
(2.0 mg/ml); lane 7, peptide B (10 mg/ml).
FIG. 5. Competition for binding of IGFBP-3 to ECM. IGFBP-3,
80 ng/ml, was incubated with ECM in the presence of increasing con-
centrations of peptides A and B and the ECM-bound IGFBP-3 deter-
mined by immunoblotting as described under “Experimental Proce-
dures.” Lane 1, ECM alone; lanes 2–6, IGFBP-3 (80 ng/ml); lane 3,
peptide A (0.45 mg/ml); lane 4, peptide A (4.5 mg/ml); lane 5, peptide B
(0.45 mg/ml); lane 6, peptide B (4.5 mg/ml).
FIG. 6. A and B, competition for binding using radiolabeled IGFBP-3
and -5. Increasing concentrations of IGFBP-5 (A), IGFBP-3 (B), or
peptide A (E– –E) were incubated with 125I-IGFBP-3 or -5, and binding
was determined as described under “Experimental Procedures.” Spe-
cific binding was determined by subtracting the counts/min bound in
the presence of a 300 pM concentration of each protein. The results are
expressed as the percentage bound, and this was determined by divid-
ing the counts/min bound using each concentration of unlabeled protein
by the counts/min bound when 125I-IGFBP-3 or -5 was added alone.
FIG. 7. A, proteolysis of IGFBP-5 in the binding assay buffer. The
buffer was removed at the end of the binding assay, and IGFBP-5
content was determined by immunoblotting. Lanes 1–5, IGFBP-5 (80
ng/ml). Lanes 2–5, peptide A (0.45 mg/ml); lane 3, 3,4-DCI (5 mM); lane
4, a1-antichymotrypsin (100 mg/ml); lane 5, PB-145 (165 mg/ml). The
results show that IGFBP-5 remaining in the assay buffer is degraded.
If peptide A is added, the fragments are more abundant, whereas if
3,4-DCI or PB-145 is added with peptide A, intact IGFBP-5 band
intensity is increased. B, IGFBP-5 remaining in the ECM. Pure
IGFBP-5 was incubated with ECM (lanes 1–6) and peptide A (lanes
2–6) (0.45 mg/ml). The IGFBP-5 remaining in the ECM was determined
by immunoblotting. Serine protease inhibitors 3,4-DCI (5 mM) (lane 3),
a1-antichymotrypsin peptide (100 mg/ml) (lane 4), PB-145 (165 mg/ml)
(lane 5), and heparin (10 mg/ml) (lane 6) were added to the incubation
buffer. The ECM that was exposed to IGFBP-5 plus peptide A (lane 2)
contains fragments of 24 and 27 kDa. The corresponding control extract
of ECM exposed to IGFBP-5 only (lane 1) does not contain these bands.
When 3,4-DCI and PB-145 but not a1-antichymotrypsin are added with
peptide A, the proteolytic fragment bands are decreased in intensity.
Heparin inhibits IGFBP-5 binding to ECM.
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ECM binding (Fig. 7 and Table I). A mutant containing three
substitutions K134A, R136A, and K211N had only a slightly
greater reduction in binding (e.g. 53 6 12%) than the K211N
substitution. Further substitutions for basic residues in the
peptide A region, e.g. K211N,R214A,K217A,R218N or
K202N,K206A,R207A had greater effects (e.g. 88 6 7% and 79
6 6% respectively). To further analyze the specificity of the
effect of peptide A, competition studies were performed using
two peptides that were identical with peptide A except that
they contained substitutions for Lys211 3 Ala or Lys207 and
Lys2113 Ala. When compared to nonmutated peptide A, these
two mutant peptides were much less effective in inhibiting the
binding of IGFBP-5 to the ECM (Fig. 8). Peptide A reduced
IGFBP-5 binding by 83%, but the altered peptides reduced
binding by only 47 and 49%. This confirms that Lys211 is
important for IGFBP-5 binding to ECM. To confirm these
changes in ECM binding, immunoblotting was performed. The
results show that the relative changes in the amount of each
mutant that was associated with the ECM (Fig. 9) were similar
to those obtained using ligand blotting (Fig. 8). For example,
K211N,R214A,K217A,R218N-IGFBP-5 showed the greatest re-
duction in binding while the K211N and K134A,R136A mu-
tants showed the least. Immunoblotting of the assay buffer for
each experimental determination showed that the wild type
and mutant forms of IGFBP-5 were minimally degraded (e.g.
,10% of total), and no mutant was degraded preferentially
compared to wild type IGFBP-5.
To verify these quantitative differences in ECM binding be-
tween the various mutants and nonmutated IGFBP-5, equilib-
rium binding assays were performed using increasing concen-
trations of each mutant and determining the amount of
IGFBP-5 that was bound to ECM by phosphoimage analysis.
As shown in Fig. 10 and Table II, when the mutants were
tested over a wide range of concentrations, each had lower
binding to ECM compared with wild type IGFBP-5. The mu-
tants with substitution for 3 or 4 basic residues in the peptide
A region had the greatest reduction. The reductions in ECM
binding for 3 mutants K211N,K134A,R136A, K202N,K206A,
R207A, and K211N,R214A,R217A,R218N as compared to non-
mutated IGFBP-5 were similar to the decreases shown in the
experiment in Fig. 7. The K134A,R136A mutant showed less
reduction in binding to the ECM compared to the results shown
in Fig. 7. When the assay buffer obtained at the completion of
the incubation was analyzed by immunoblotting, there were
minimal differences in the amount of fragment that was de-
tected when the mutants and wild type IGFBP-5 were com-
pared and the amount of fragment was consistently ,10% of
the total (data not shown).
DISCUSSION
These results show that two regions of IGFBP-5 (Arg201-
Arg218 and Ala131-Thr141) that contain several basic amino
acids are important for its attachment to ECM. Peptide A was
4.1-fold more potent than peptide B in inhibiting IGFBP-5
binding to ECM and 20-fold more potent than peptide B in
inhibiting IGFBP-3 binding. Since the peptide A sequence is
the same within IGFBP-3 and IGFBP-5 and is not contained in
the other forms of IGFBPs that do not bind to fibroblast ECM,
this sequence has unique determinants for IGFBP-3 and
IGFBP-5 ECM binding (5). This binding does not appear to be
solely due to electrostatic interaction, since peptide B which
has a charge to mass ratio that is similar to peptide A is less
potent.
More definitive proof of the importance of the peptide A
region in mediating attachment to ECM was provided by uti-
lizing site-directed mutagenesis. Mutations in the peptide A
region caused significant reductions in ECM binding. A single
substitution K211N was effective, but a mutant containing four
substitutions, K211N,R214A,K217A,R218N, had the greatest
reduction. Substitution for basic residues at positions 202, 206,
and 207 gave an intermediate result. These differences were
noted over a wide range of IGFBP concentrations and therefore
are unlikely to be due to differences in the estimation of protein
concentration. Taken together, the findings strongly suggest
that several basic residues within this 18-amino acid region are
important for ECM binding and that the positional location of
TABLE I
Binding affinity of each mutant for IGF-I and reduction in ECM binding
The affinity of each mutant for IGF-I was determined by Scatchard analysis. The fold change is the ratio of the affinity of the mutant divided
by the affinity of nonmutated IGFBP-5. The stoichiometry of each mutant was determined to be 1:1. The percentage reduction in ECM binding was
determined by dividing the band intensity on Western ligand blotting, as shown in Fig. 6, by the band intensity of control, nonmutated IGFBP-5.
The affinity of nonmutated IGFBP-5 was 3.8 3 1010 liters/mol. Each value represents the mean 6 S.D. of 3 separate experimental determinations.
Mutant forms of IGFBP-5 Fold change in IGF-I affinity Reduction in ECM binding
%
K211N 1.1 49 6 13
K211N,K134A,R136A 1.1 53 6 12
K134A,R136A 1.6 40 6 11
K202N,K206A,R207A 1.1 79 6 6
K211N,R214A,R217A,R218N 1.2 88 6 7
FIG. 8. Ligand blot of binding of IGFBP-5 mutants to ECM.
Fibroblast ECM was prepared as described in Fig. 2. Each mutant (80
ng/ml) was incubated overnight with the ECM as described under
“Experimental Procedures.” The ECM was extracted, and IGFBP-5
binding was determined by SDS-PAGE followed by ligand blotting. The
arrow denotes the position of the IGFBP-5 bands. Lane 1, IGFBP-5;
lane 2, K211N; lane 3, K211N,R214A,K217A,R218N; lane 4, K134A,
R136A; lane 5, IGFBP-5; lane 6, K202N,K206A,R207A; lane 7, IGFBP-5;
lane 8, K134A,R136A,K211N; lane 9, IGFBP-5; lane 10, IGFBP-5 plus
peptide A, 4.5 mg/ml; lane 11, plus K211A-peptide A; lane 12, plus
K207A,K211A peptide A. Since the figure is a composite of 4 separate
autoradiographs, the control lane for each separate autoradiograph
that contained nonmutated IGFBP-5 is shown (lanes 1, 5, 7, and 9).
FIG. 9. Immunoblot of binding of IGFBP-5 mutants binding to
ECM. Intact or mutant forms of IGFBP-5 (80 ng/ml) were incubated
overnight with fibroblast ECM as in Fig. 6. Analysis of binding was
performed by SDS-PAGE followed by immunoblotting. Lane 1,
IGFBP-5; lane 2, K211N; lane 3, IGFBP-5; lane 4, K134A,R136A;
lane 5, K202N,K206A,R207A; lane 6, IGFBP-5; lane 7, K211N,R214A,
K217A,K218N; lane 8, K134A,R136A,K211N.
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these charged residues may be important.
Peptide B which contained six basic amino acids was an
effective inhibitor of IGFBP-5 association with ECM but does
not inhibit its binding to heparin (7). Mutagenesis of two basic
residues, Lys134 and Arg136, within the peptide B region re-
sulted in a 25% reduction in ECM binding and competition
studies using peptide B and this mutant showed no additional
decrease in binding. This indicates that additional peptide B
region substitutions probably would have had no additional
effect. A mutant that combined the K134A,R136A substitutions
with K211N showed only a slightly greater effect than the
K211N substitution alone. These findings suggest the peptide
B region is less important for binding to ECM.
The peptide A region of IGFBP-5 and IGFBP-3 contains the
heparin binding domain BBBXXB where B represents basic
amino acids and X represents neutral residues. This motif is
present in several proteins that are known to bind to heparin
(19), and it would be predicted that proteins that contain this
sequence might bind to glycosaminoglycans that are present in
the ECM. This conclusion is further supported by our observa-
tion that IGFBP-5 binds to heparan and heparan sulfate and
that peptide A is a potent inhibitor of IGFBP-5 binding to
heparin (7). In contrast, peptide D which contains the heparin
binding motif BBXB had no effect on IGFBP-5 binding to ECM
suggesting that the effect of the BBBXXB sequence is specific.
The fact that both the K211N and the K202N,K206A,R207N
substitutions resulted in decreased binding suggests that res-
idues 206, 207, and 211 within this region are important for
IGFBP-5 association with ECM. However, the K211N,R214A,
R217A,R218N mutant had a greater loss of ECM binding than
K211N indicating that basic residues other than those in this
linear heparin binding sequence motif are also important. Fur-
ther mutational analysis will be required to define the exact
location of the amino acids that are required for ECM binding
and whether these are the same residues that mediate glycos-
aminoglycan binding (7).
Previous studies have shown that the association of IGFBP-5
with ECM results in a reduction in its affinity for IGF-I and
enhancement of IGF-I-stimulated cell growth. (5) Since the
IGF-I binding site within IGFBP-5 is unknown, it was not clear
whether mutagenesis of basic residues in peptide A or B re-
gions of IGFBP-5 might alter its affinity for IGF-I. When we
analyzed the affinity of each mutant for IGF-I, only the
K134A,R136A mutant had any change and the increase (e.g.
1.6-fold) was minimal.
IGFBP-5 association with ECM also appears to alter its
sensitivity to proteolysis. Immunoblotting shows no fragments
of IGFBP-5 in fibroblast ECM, whereas a non-IGF-I-binding
22-kDa fragment is abundant in conditioned medium (6). Like-
wise, incubation of the 22-kDa purified IGFBP-5 fragment with
ECM results in no detectable binding (6). This suggests that
either that ECM-associated IGFBP-5 is resistant to proteolytic
cleavage or that the fragment is completely released after pro-
teolysis. However, competition with peptide A resulted in the
appearance of larger fragments (e.g. 24 and 27 kDa) that were
present in the binding buffer and in the ECM. Their appear-
ance could be inhibited by the addition of a serine protease
inhibitor to the incubation buffer (Fig. 7, lane 3) suggesting
that they originate as the result of proteolytic cleavage. These
findings suggest that a serine protease that can cleave
IGFBP-5 is present in ECM; however, during usual assay con-
ditions (e.g. 80 ng/ml IGFBP-5 added) there is not sufficient
protease released to detect IGFBP-5 fragments in the incuba-
tion buffer. If more IGFBP-5 is added (e.g. 800 ng/ml), then the
intensities of the fragment bands are increased but .90% of
the IGFBP-5 is still intact and there are only minimal differ-
ences between the mutants and nonmutated IGFBP-5 in frag-
ment abundance. This shows that the mutants are not de-
graded more rapidly and increased proteolysis does not account
for their reduced ECM binding. This serine protease is distinct
from the serine protease in fibroblast media (18) since its
activity is not inhibited by a1-antichymotrypsin or EDTA. The
exact role of this ECM-associated protease in controlling
IGFBP-5 abundance will require further study.
Other growth factors such as fibroblast growth factor (FGF)
(20), transforming growth factor b (TGF-b) (21), interleukin 3,
and granulocyte/macrophage colony stimulating factor have
been shown to associate with ECM components. TGF beta
binds to a glycoprotein, betaglycan (21), that is present in
ECM, whereas FGF associates with heparan sulfate side
chains of ECM proteins, such as heparan sulfate proteoglycan
(22). Association of TGF-b, FGF, interleukin 3, and granulo-
cyte/macrophage colony stimulating factor with ECM compo-
nents has been shown to result in enhancement of the cellular
responses to these growth factors (23–25). Similarly, proteases,
such as tissue plasminogen activator, plasmin, or thrombin
(26), as well as protease inhibitors, such as plasminogen acti-
vator inhibitor (27), have been shown to bind to specific ECM
components. This suggests that systems exist for controlled
release of these growth factors or their binding proteins from
the ECM. Our findings suggest that the IGFBP-5/IGF-I system
may be under the control of similar variables.
Our previous studies have shown that the activity of an
IGFBP-5 protease that is secreted by fibroblasts is specifically
inhibited by heparin and heparan sulfate (28). Since our results
show that ECM proteoglycans also bind IGFBP-5, this binding
may have dual functions, e.g. focal localization of IGFBP-5 in
FIG. 10. ECM binding activity of mutant forms of IGFBPs.
Increasing concentrations (80, 160, 320, and 800 ng/ml) of native
IGFBP-5 (lanes 1–4) or mutant forms (lanes 5–8) were incubated with
fibroblast ECM, and binding was determined as described under “Ex-
perimental Procedures.” The figure shows the ligand blot band inten-
sity for native IGFBP-5 and the form of each mutant that was used in
that particular experiment. The mutants that were tested include: A,
K134A,K136A; B, K211N; C, K134A,K136A,K211N; D, K202N,K206A,
R207A; and E, K211N,R214A,K217A,R218N.
TABLE II
ECM binding of IGFBP-5 mutants
The values are expressed as the percentage of control nonmutated
IGFBP-5 binding for that individual experiment. They were obtained by
determining the amount of each mutant form of IGFBP-5 that bound to
ECM and dividing it by the amount of nonmutated IGFBP-5 that bound
in the same experiment. Binding was quantified by phosphoimage
analysis, and each value represents the mean of 3 experiments. A
representative experiment is shown in Fig. 10.
Mutant Form of IGFBP-5
IGFBP-5 added (ng/ml)
80 160 320 800
% control IGFBP-5 binding
K134A,R136A 76 82 76 73
K211N 55 42 55 65
K134A,R136A,K211N 41 41 47 54
K202N,K206A,R207A 38 32 29 31
K211N,R214A,K217A,R218N 5 5 10 7
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ECM and protection from proteolysis. Both protection from
proteolysis and conformational changes that reduce IGFBP-5
affinity are functions of ECM binding that would result in
increased amounts of IGF-I being available to bind to receptors.
Therefore, determining the matrix binding sites within
IGFBP-5 may provide insights regarding the physiologic func-
tion of this protein in ECM and these mutants should be of help
in discerning the mechanism by which ECM-sequestered IGF-I
is presented to cell surface receptors.
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